Search
Akebia Therapeutics Inc
AKBAAdd to Watchlist
1.240USD
+0.030+2.48%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
332.19MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.48%
5 Days
+8.77%
1 Month
+27.80%
6 Months
-20.00%
Year to Date
-22.98%
1 Year
-65.75%
Key Figures
1.220Open
1.240High
4.20MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.57%Turnover Ratio
1.210Prev. Close
1.160Low
3.69MTurnover
LossP/E Static
12.13P/B
0.00%Div Yield TTM
-6.10%ROA
4.07952wk High
1.09Volume Ratio
-69.41MNet Profit
267.90MShares
-0.0806EPS TTM
0.28Beta
-78.96%ROE
0.87552wk Low
6.61%Amplitude
69.75%Gross Margin
332.19MMarket Cap
6.78Reward/Risk
3.64%Risk Rate
TradingKey Stock Score of Akebia Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Akebia Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 56 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 4.20.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Akebia Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Akebia Therapeutics Inc Highlights
StrengthsRisks
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.36% year-on-year.
Undervalued
The company’s latest PE is -15.38, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 125.97M shares, decreasing 10.60% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 36.67K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.68.
Analyst Rating
Based on
5
analysts
Strong Buy
Current Rating
4.200
Target Price
+247.11%
Upside Space
Akebia Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Akebia Therapeutics Inc Info
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Ticker SymbolAKBA
CompanyAkebia Therapeutics Inc
CEOButler (John P)
Websitehttps://akebia.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Akebia Therapeutics Inc (AKBA)?
The current price of Akebia Therapeutics Inc (AKBA) is 1.24.
What is the symbol of Akebia Therapeutics Inc?
The ticker symbol of Akebia Therapeutics Inc is AKBA.
What is the 52-week high of Akebia Therapeutics Inc?
The 52-week high of Akebia Therapeutics Inc is 4.08.
What is the 52-week low of Akebia Therapeutics Inc?
The 52-week low of Akebia Therapeutics Inc is 0.88.
What is the market capitalization of Akebia Therapeutics Inc?
The market capitalization of Akebia Therapeutics Inc is 332.19M.
Is Akebia Therapeutics Inc (AKBA) currently rated as Buy, Hold, or Sell?
According to analysts, Akebia Therapeutics Inc (AKBA) has an overall rating of STRONG BUY, with a price target of 4.20.
What is the Earnings Per Share (EPS TTM) of Akebia Therapeutics Inc (AKBA)?
The Earnings Per Share (EPS TTM) of Akebia Therapeutics Inc (AKBA) is -0.02.